{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"32","value":"9.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"ICU inpatient"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"58","value":"11.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"non-ICU inpatient"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Total length of all intensive care unit (ICU) and non-ICU stays from JCARH125 Administration. ICU inpatient and non-ICU inpatient are not exclusive. Total length includes participants who had multiple hospitalization stays.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion to up to approximately 61 months","title":"Duration of Hospitalization From JCARH125 Administration in Phase 2","type":"SECONDARY","unitOfMeasure":"Days"}